Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomePreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Gains from Investment Securities (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Gains from Investment Securities for 12 consecutive years, with $101000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities changed N/A to $101000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$101000.0 through Sep 2025, up 97.62% year-over-year, with the annual reading at $7.1 million for FY2021, 58.44% up from the prior year.
  • Gains from Investment Securities hit $101000.0 in Q4 2025 for vTv Therapeutics, up from -$34000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $7.1 million in Q4 2021 to a low of -$4.2 million in Q4 2023.
  • Historically, Gains from Investment Securities has averaged $1.4 million across 5 years, with a median of $49000.0 in 2021.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 5087.71% in 2021 and later crashed 221.43% in 2025.
  • Year by year, Gains from Investment Securities stood at $7.1 million in 2021, then dropped by 18.9% to $5.7 million in 2022, then crashed by 174.18% to -$4.2 million in 2023, then surged by 100.66% to $28000.0 in 2024, then skyrocketed by 260.71% to $101000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for VTVT at $101000.0 in Q4 2025, -$34000.0 in Q3 2025, and -$34000.0 in Q2 2025.